Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/29/23 | Current report filing |
|
 |
41 | |
| 09/29/23 | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
2 | ||
| 09/29/23 | Current report filing |
|
|
6 | |
| 09/06/23 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 09/06/23 | Initial statement of beneficial ownership of securities |
|
2 | ||
| 09/06/23 | Current report filing |
|
|
5 | |
| 08/16/23 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 08/08/23 | Quarterly report pursuant to Section 13 or 15(d) |
|
|
49 | |
| 08/07/23 | Current report filing |
|
|
8 | |
| 07/24/23 | Statement of changes in beneficial ownership of securities |
|
1 |